MetaVia Inc. logo

MetaVia Inc.(MTVA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.3
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MTVA

11/13/2026: MTVA (1-star) is currently NOT-A-BUY. Pass it for now.

MetaVia Inc. is a micro-cap clinical-stage biotechnology company focused on developing therapies for cardiometabolic diseases like obesity and MASH. Its business model relies on the successful progression of pipeline candidates such as DA-1726 and vanoglipel, which are currently being evaluated in clinical trials. The company's primary strength lies in its specialized research focus, while its most significant risk is the absence of commercial revenue, which necessitates ongoing, potentially dilutive financing. Given its pre-revenue status and high execution risk, this stock is generally suited only for speculative investors with a high risk tolerance. Investors should monitor clinical trial data releases and the company's capital management as key indicators of viability.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThis is a speculative growth play dependent on future clinical successes rather than current fundamental growth.
Momentum investorWeak fitMomentum is limited by high volatility and the lack of consistent upward price trends.
Value investorWeak fitThe lack of revenue and earnings makes traditional valuation metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and is unlikely to do so in the near future.
Low-risk investorWeak fitThe high clinical, financial, and volatility risk profile is unsuitable for low-risk investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is subject to significant daily price swings typical of micro-cap biotech.
Valuation riskHighValuation is highly speculative and tied to unproven clinical outcomes.
Competition risk (Biotech)HighWell-funded incumbents dominate the cardiometabolic treatment landscape.
Business qualityLowThe company is pre-revenue and depends entirely on successful R&D.
Dividend incomeLow / noneThere is no income generation for shareholders.
Execution riskHighClinical trial delays or failures could effectively end the company's business model.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.56M USD
Price to earnings Ratio -
1Y Target Price 19.33
Price to earnings Ratio -
1Y Target Price 19.33
Volume (30-day avg) 150.5K shares
Beta 1.24
52 Weeks Range 0.97 - 13.42
Updated Date 11/14/2026
52 Weeks Range 0.97 - 13.42
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.65

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -49.86%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MTVA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
MTVA has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+53.0%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
MTVA's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is MTVA's strongest growth driver at +53.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+36.5%, strong) is also strong, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 13.4% and approximately 72.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 29.41% supports management-shareholder alignment.

Top 5 Institutional Investors

Jane Street Group LLC 1.88%
Citadel Advisors Llc 0.93%
Virtu Financial LLC 0.45%
Geode Capital Management, LLC 0.32%
UBS Group AG 0.20%

Unit Economics (Per $1K Revenue)

★★★★★
MTVA generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MTVA has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical R&DAdvancement of pipeline candidates like DA-1726 and vanoglipel.The company currently makes no money; it spends cash to develop drugs.
LicensingOut-licensing legacy assets like Gemcabene.Small amounts of capital may be recovered through intellectual property licensing.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3.89M
Price to Sales(TTM) -
Enterprise Value -3.89M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.43
Shares Outstanding 6.59M
Shares Floating 4.80M
Shares Outstanding 6.59M
Shares Floating 4.80M
Percent Insiders 29.41
Percent Institutions 13.39

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.